Inflammatory bowel disease (IBD) is an umbrella term for immune response-mediated chronic remission and relapse bowel diseases that result in the chronic inflammation of intestines, causing pain and swelling. Although there is no effective cure to date, there has been extensive research on IBD and gut microbiota that has led to insights that may result in effective therapeutic interventions. This new volume, Inflammatory Bowel Disease and Gut Microbiota: Current Strategies and Future Prospects in Nanomedicine, delves into the intricacies of this research, highlighting the novel methodologies and innovative approaches in the treatment of IBD in conjunction with the role of gut microbiota.
The book provides a comprehensive investigation of IBD, exploring the significance of gut microbiota in the advancement and progression of IBD. It investigates the fundamental role of microbial imbalances in the initiation and progression of inflammatory processes, as well as the prominent therapeutic consequences of restoring microbial homeostasis in the context of treatment techniques. The book explores nanotechnology and nanomedicine as a promising field in this regard. It provides a detailed overview of nanotechnological advancement for specific and efficient treatments for IBD. From nanoparticle-based drug delivery systems that advance the bioavailability of the medicaments to the use of bio-nanosensors for early detection of disease, the book covers a broad spectrum of inventions that hold potential for revolutionizing IBD treatment. The authors look at the impact of nutraceuticals, probiotics, prebiotics, functional foods, oral siRNA-based nanomedicine, and other novel drug delivery systems on gut microbiota for the management of IBD. The book also explores the role of reactive oxygen species (ROSs), superoxide dismutases (SODs), and inflammation in association with gut microbiota and IBD. The volume also anticipates future expansions, engaging in speculation on probable progresses and the obstacles that may be confronted.
Aiming to stimulate further research and collaboration across interdisciplinary channels and encouraging a better understanding of IBD, this book will prove beneficial to researchers, clinicians, students, and anyone interested in the intersection of gastroenterology, microbiology, and nanotechnology for the exploration of the current landscape and future potential of treating inflammatory bowel disease.
Covers novel methodologies and innovative approaches in treatment of IBD. Investigates IBD and significance of gut microbiota in progression of IBD. Investigates microbial imbalances and consequences of restoring microbial homeostasis as treatment. Explores nanotechnology and nanomedicine as treatment as well as future expansions.
1. Introduction to Gut Microbiota and Inflammatory Bowel Disease: A
Systematic Review
2. Pathogenesis of Gut Microbiota in Inflammatory Bowel
Disease
3. Impact of Nutraceuticals on Gut Microbiota for the Management of
Inflammatory Bowel Disease
4. Targeting Gut Microbiota with a Novel Drug
Delivery System to Treat Inflammatory Bowel Disease
5. Management of Gut
Microbiota-Derived Bacterial Metabolites Induced Inflammatory Bowel Disease
6. Correlation Between Host Genetics and Gut Microbiota in Inflammatory Bowel
Disease
7. Oral siRNA-Based Nanomedicine for the Treatment of Inflammatory
Bowel Disease
8. Site-Specific Targeted Novel Drug Delivery System for the
Management of Inflammatory Bowel Disease
9. Surface-Modified Lipid
Nanoparticle-Mediated Site-Specific Drug Delivery for Inflammatory Bowel
Disease
10. Interplay Between Autophagy, Gut Microbiota, and Inflammatory
Bowel Disease
11. Role of Reactive Oxygen Species, Superoxide Dismutases, and
Inflammation in Association with Gut Microbiota and Inflammatory Bowel
Disease
12. Composition of Gut Microbiota Dysbiosis and Functional Food to
Treat Inflammatory Bowel Disease
13. Age-Related Gut Dysbiosis and Its Impact
on Inflammatory Bowel Disease
14. Impact of Diseased Condition on Gut
Microbiota in Inflammatory Bowel Disease
15. Role of Probiotics and
Prebiotics in Inflammatory Bowel Disease
16. Application of Natural Products
to Target Gut Microbiota for Inflammatory Bowel Disease Management
17. Future
Prospects and Patents of Nanomedicines in Treating Inflammatory Bowel Disease
Neeraj Mishra, PhD, is a Professor at the Amity Institute of Pharmacy, Gwalior, India. He has 20 years of teaching and research experience. A brand ambassador at Bentham Science, he has published more than 100 papers on recent concepts of novel drug delivery systems, oral delivery of synbiotics, localized drug delivery, targeted and controlled drug delivery of nanocarriers/microparticles for the treatment of breast and colon cancer, and neurodegenerative disorders. He has also written more than 15 books and 25 book chapters and has been granted several patents. He was a recipient of an Indian Council of Medical Research Senior Research Fellowship and a Distinguished Professor Award from the Indian Department of Science and Technology, National Science and Technology Management Information System, Synergizing Pharma Academic-Industry Collaboration Systems.
Sumel Ashique, MPharm, is a Research Scholar at the School of Pharmaceutical Sciences at Lovely Professional University, Punjab, India, where he is pursuing his PhD. His research area is probiotics, postbiotics, gut microbiota, and inflammatory disorders. With knowledge in drug delivery, nanotechnology, and targeted treatment strategy, he has four years of teaching experience and has published book chapters with international publishers and over 100 papers in accredited reputed journals. He has also six granted intellectual property (IP) patents from IP India and Australia. He is currently editing 13 books with Apple Academic Press, CRC Press, Taylor and Francis, and others.
Ashish Garg, PhD, is a Professor at the Guru Ramdas Khalsa Institute of Science and Technology (Pharmacy), Jabalpur, M.P., India. He has around ten years of teaching and research experience and has 80 publications in national and international journals of repute. He has authored 27 book chapters and edited several books on recent concepts of nanotechnology, novel drug delivery systems, cancer targeting, etc. Dr. Garg has been granted three international patents and has published three Indian patents. He also acts as an editorial board member and reviewer for several journals.
